Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

MCI USA Welcomes New Client Optica to Convention Division


News Image

MCI USA’s convention division is pleased to partner with Optica, a global society for professionals in optics and photonics. MCI USA will provide registration and housing services for Optica’s OFC Conference & Exhibition, as well as the CLEO Conference & Exhibition, in 2023 through 2025. With more than 22,000 individual members and 290 corporate members, Optica’s mission is to promote the generation, application and archiving of knowledge in optics and photonics and to disseminate this knowledge worldwide.

“MCI USA is thrilled to be working with Optica,” said Laura Beckum, SVP, Business Development, MCI USA. “This partnership allows us to use our industry-leading registration and housing platform, OneSystem Plus, to provide solutions that will improve the client user experience, as well as the experience of the registrants and those making housing reservations.”

Optica has helped academia and industry collaborate for over 100 years. Since 1916, the organization has championed optics and photonics, uniting and educating scientists, engineers, educators, technicians and business leaders around the world to foster and promote technical and professional development. OFC, the premier event in telecom and data center optics, is the largest global conference and exhibition for optical communications and networking professionals. Optica is a co-sponsor of the Conference on Lasers and Electro-Optics, or CLEO, an international forum for scientific and technical optics, uniting the fields of lasers and opto-electronics by bringing together all aspects of laser technology, from basic research to industry applications.

For over 30 years, MCI USA’s convention division has been providing registration, housing, lead cultivation, and business intelligence solutions to events of all sizes and complexity around the world. MCI’s registration and housing services are powered by OneSystem Plus, the industry’s most complete and customizable registration and housing platform.

ABOUT MCI 

MCI is a global engagement and marketing agency. We design human-centric solutions that unleash the power of people to deliver innovation and growth for our clients. Our offering includes live & virtual events, strategic & digital communications, consulting & community solutions. We help brands, companies, associations and not-for-profits solve their challenges, bringing their people together to shape their tomorrow. MCI is an independently owned company headquartered in Geneva, Switzerland, with a global presence in 60 offices across 31 countries. http://www.wearemci.com 

MCI’s U.S. headquarters is in the Washington, D.C., area with offices in New York, Baltimore, Dallas, and Chicago. http://www.wearemci.com/en-us

Share article on social media or email:

Avokadio Launches Pocket-sized Nutritionist, Uses AI-based Breath Analysis Technology


News Image

“Everyone’s body, health and metabolism are different, Avokadio is here to make a difference and optimize your health, starting with a single breath.”

Breathe into wellness with Avokadio, launching today on Indiegogo. Avokadio is a portable device that combines hardware and a mobile app to offer artificial intelligence-backed nutritional advice based on breath biomarker analysis. The breath analysis technology measures the ketones in a user’s breath to track their fat-burning metabolism and provide user-specific recommendations such as weekly meal plans and basic exercises to help achieve wellness goals.

The prevalence of wearable wellness devices such as smartwatches, patches and smart rings has led to an overload of generalized data that doesn’t allow people to implement scientific metrics into their daily routine, nutrition and exercise. Avokadio is a wearable wellness device that simplifies the scientific metrics and provides a personalized wellness experience through advice, evolving nutritional plans, and basic exercise recommendations.

Users are encouraged to track three to four breath measurements per day, ideally an hour post-meal, to allow Avokadio’s AI algorithm to learn more about the user, their body’s fat-burning metabolism and how they process the food they eat. The nano-tech ketone sensors measure a user’s fat-burning ketones with Avokadio’s easy-to-understand scoring system. The higher the score, the higher the user’s fat-burn rate, allowing them to track the user’s health and progress. The scoring system is:

1: No Fat Burn

2-4: Low Fat Burn (Low Ketosis)

5-7: Moderate Fat Burn (Moderate Ketosis)

8-10: High Fat Burn (High Ketosis)

As Avokadio gathers more data and learns more about a user’s body, it provides basic exercise recommendations and a personalized approach to meals.

“Diets are stressful and restrictive so we want to simplify and help people breathe into wellness,” said Avokadio creator and co-founder, Dr. Gokcen Garipoglu. “Everyone’s body, health and metabolism are different, Avokadio is here to make a difference and optimize your health, starting with a single breath.”

Avokadio offers a 12-month subscription on the smart app, available to download for free on iOS and Android devices, where users can actively follow their personal data to understand their nutrition, exercise and eating habits. Plus, the meal plans adapt based on a user’s preferences and dietary restrictions, as well as their real-time Avokadio fat-burning score.

The Avokadio team has conducted two clinical trials and published a research-proven paper to support the AI-generated analysis and feedback. To pre-order visit, pr.go2.fund/avokadio.

About Avokadio

Avokadio is a lifestyle and wellness brand that works to bring personalized nutrition, exercise and eating habits available to everyone. Based on science and clinical trials, Avokadio takes pride in their technology that allows a simple breath to track a user’s fat-burning metabolism and provide user-specific recommendations utilizing the ketone count in the body. Avokadio is here to make a difference and optimize users’ health–just by a single breath. For more information, visit https://www.avokad.io/.

Share article on social media or email:

COVID-19 Vaccination Linked to Fewer Cardiac Events; First U.S. study to show lower risk in patients following SARS-CoV-2 infection


Analyzing the most extensive datasets in the United States, researchers from the Icahn School of Medicine at Mount Sinai have revealed that vaccination against COVID-19 is associated with fewer heart attacks, strokes, and other cardiovascular issues among people who were infected with SARS-CoV-2, the virus that causes COVID-19.

The research letter, “Impact of Vaccination on Major Adverse Cardiovascular Events in Patients with COVID-19 Infection,” was published in the Journal of the American College of Cardiology on February 20 (DOI: 10.1016/j.jacc.2022.12.006).

In addition, the research will be presented in a poster session in New Orleans, LA, at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology:


Title – Prevention and Health Promotion: Population Science

Date/Time – March 5, 2023, 9:30 am to 10:30 am *Central Time*

Location – Poster Hall, Hall F

It is the first study to examine both full and partial vaccination and the link to major adverse cardiac events (MACE) in the United States, confirming similar analyses performed previously using the Korean COVID-19 registry. Researchers used the National COVID Cohort Collaborative (N3C) database, the largest national comprehensive database on COVID-19. Since its inception in 2020, the N3C has continuously collected and harmonized data from electronic health records of institutions across the country. Included in this study were 1,934,294 patients, 217,843 of whom received mRNA vaccine formulations by Pfizer-BioNTech or Moderna or viral vector technology by Johnson & Johnson. Cox proportional hazards, a statistical technique, was implemented to assess vaccination association with MACE.

“We sought to clarify the impact of previous vaccination on cardiovascular events among people who develop COVID-19 and found that, particularly among those with comorbidities, such as previous MACE, type 2 diabetes, high cholesterol, liver disease, and obesity, there is an association with a lower risk of complications. While we cannot attribute causality, it is supportive evidence that vaccination may have beneficial effects on a variety of post-COVID-19 complications,” said senior author Girish N. Nadkarni, MD, MPH, Irene and Dr. Arthur M. Fishberg Professor of Medicine at Icahn Mount Sinai, Director of The Charles Bronfman Institute of Personalized Medicine, and System Chief, Division of Data Driven and Digital Medicine (D3M), Department of Medicine.

“To our surprise, even partial vaccination was associated with lower risk of adverse cardiovascular events,” said first study author Joy Jiang, an MD/PhD candidate in the lab of Dr. Nadkarni. “Given the magnitude of SARS-CoV-2 infection worldwide, we hope our findings could help improve vaccination rates, especially in individuals with coexisting conditions.”

Further work will be necessary to elucidate the mechanisms involved from an immunological perspective and clarify the role of SARS-CoV-2 subtypes and reinfections in their relationship to the risk of MACE.

Additional co-authors are Lili Chan, MD, MS; Justin Kauffman, BS; Jagat Narula, MD, PhD; Alexander W. Charney, MD, PhD; and Wonsuk Oh, PhD, all from Icahn Mount Sinai.

The work was supported, in part, by funds from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, grant numbers K23DK124645 and T32DK007757, and by the TL1 Career Development Award, 1TL1TR004420-01.

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.

Ranked No. 14 nationwide in National Institutes of Health funding and in the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 34 academic departments and 44 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, and gastrointestinal and liver diseases.

Icahn Mount Sinai offers highly competitive MD, PhD, and master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. In addition, more than 535 postdoctoral research fellows are in training within the Health System.

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into health care products and services that benefit the public.

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

——————————————————-

  • Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

VerImmune, Inc. Announces Issuance of Second U.S Patent Protecting Proprietary Technology Platform


VerImmune, Inc. (“VerImmune”), a biotechnology company leading the way in developing virus-inspired particle modalities for cancer treatment, is proud to announce the issuance of its second U.S. Patent from the U.S. Patent and Trademark Office (USPTO). The newly issued patent, U.S. Patent No. 11,560,408 entitled “Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors,” provides further protection and support for VerImmune’s proprietary technology platform, including the composition of matter and methods of use in treating cancer. The patent is expected to offer protection until at least 2038.

VerImmune’s platform redirects the body’s pre-existing T-cell memory against pathogens to attack cancer and could potentially act against multiple types of cancer due to the near-universal nature of pre-existing responses to childhood vaccines and past infections. As such, this technology has potentially broad treatment applications.

“The issuance of this second patent is a testament to VerImmune’s growing global intellectual property estate, now boasting over 30 patent applications worldwide. This is a key factor in VerImmune’s mission to innovate and optimize the clinical and commercial potential of its assets.” said Joshua Wang, Founder and CEO of VerImmune.

About VerImmune

VerImmune is a biotechnology company developing a novel first-in-class cancer therapy known as Anti-tumor Immune Redirection (AIR). This strategy utilizes a proprietary virus-inspired particle (ViP) technology platform that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. This unique mechanism of action allows differentiation within the competitive Immuno-Oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have un-treatable cancers due to limited options or experience cancer treatment resistance. For more information, visit http://www.verimmune.com

Forward-Looking Statements

Any statements in this release that are not historical facts may be considered to be “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding the market opportunity for VerImmune’s product candidates; and the business strategies and development plans of VerImmune. Some of the potential risks and uncertainties that could cause actual results to differ from those expected include VerImmune’s ability to: make commercially available its products and technologies in a timely manner or at all; enter into other strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, VerImmune does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Share article on social media or email:

Captiva Spine Expands Management Team to Support Roll-Out of the New WatchTower™ Spine Navigation and Robotics System


WatchTower Spine Navigation and Robotics System

The WatchTower™ System is a synergistic addition to support our newest generation of TowerLOX-EXT MIS Extended Tab Pedicle Screws.

The WatchTower Spine Navigation and Robotics System eliminates the need for intraoperative CT imagery. This offers exceptional procedural efficiency, radiation safety, and cost-effective navigation…

Captiva Spine is a medical device organization located in Jupiter, Florida, dedicated to delivering smart, elegant, and intuitive spinal fusion solutions. Today Captiva Spine announced the expansion of its management team to accelerate the roll-out of its WatchTower Spine Navigation and Robotic System. Daniel McPhillips has joined Captiva Spine as the Director of Enabling Technologies and Market Development.

“Dan will be a great asset to the roll-out of the WatchTower Spine Navigation and Robotics System,” said Dale Mitchell, President of Captiva Spine. “Dan has been at the forefront of numerous technological inflection points in the spine market going back to the first MIS pedicle screw systems and cage IDE/PMAs. His most recent experience focused on innovations in percutaneous interbody fusion.”

The WatchTower Spine Navigation System promises to provide surgeons with a next-generation navigation and robotics system for the Ambulatory Surgery Center (ASC) and specialty hospital. WatchTower Spine Navigation eliminates the need for inter-operative CT imagery. This offers exceptional procedural efficiency, radiation safety, and a cost-effective navigation solution for these new service sites. The spine navigation system has received 510(k) clearance from the FDA (U.S. Food and Drug Administration) and is available for commercial use.

“Spinal fusion procedures have become less invasive and post-operative significantly more effective, making same-day lumbar fusion surgery a reality,” said Dan McPhillips. “This, along with the recent changes in the CMS in-patient-only list, makes ASC MIS spinal fusion a real opportunity for surgeons and patients. I am excited to join Captiva because the WatchTower Spine Navigation and Robotics System offer advanced spine navigation capabilities yet are economically practical for the ASC setting.”

Vertical Integration at Captiva Spine

“At Captiva Spine, we always strive to provide smart, elegant, and intuitive spinal solutions, but more than that, we are working to provide a solid vertically integrated procedural platform,” said Dale Mitchell. The WatchTower System is a synergistic addition to support our newest generation TowerLOX-EXT MIS Extended Tab Pedicle Screw System and TransFasten Posterior SI Joint Fusion System.”

TowerLOX-EXT is the next-generation extended tab MIS screw system from Captiva Spine. It affords the surgeon the state-of-the-art MIS extended tab design they expect with significantly more reduction and spinal re-alignment utility than other systems on the market.

The TransFasten Posterior SI Fusion System is a unique approach to posterior MIS sacroiliac joint fusions, offering increased efficiency while reducing the invasiveness of traditional sacroiliac joint fusions. The system’s patented carpentry has been developed to ensure ease of use, immediate stabilization of the motion segment, and an optimal environment for fusion. Experience the benefits of TransFasten for yourself and discover how our innovative system may help achieve the results patients are looking for.

__________

To take advantage of Captiva Spine’s innovative technologies and incorporate them into your healthcare offerings, please don’t hesitate to reach out to us. We welcome inquiries from healthcare providers, surgical facilities, and distribution professionals. To get in touch with us directly, please email our team at info@captivaspine.com

See More Details

About Captiva Spine, Inc.

Captiva Spine, founded in 2007, is a privately owned medical device company that brings healthcare providers, distribution professionals, and surgical facilities together with innovative spinal care solutions. With a focus on quality, Captiva Spine strives to build and maintain sincere, honest, and collaborative relationships to earn mutual trust and openness. By doing so, we aim to become the preferred provider of smart, elegant, and intuitive spine care solutions.

Share article on social media or email:

The Pediatric Asthma Risk Score Can Help Predict Asthma Development in Children


AAAAI Logo

Essentially what we saw was that the original PARS scoring was similar to scoring in the new, more diverse cohorts. This validates our previous results and could lead to PARS ultimately becoming a new quantitative gold standard in pediatric asthma risk prediction.

Researchers have confirmed the effectiveness of the Pediatric Asthma Risk Score (PARS) after validating its use with diverse cohorts from across the United States. The results are being presented in full during the 2023 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).

“If we hope to initiate early prevention strategies, it is essential that we predict asthma as early as possible,” said Jocelyn M. Biagini, PhD, primary author of the study. “PARS is a continuous score that was developed to predict early-life asthma. We wanted to validate the results in cohorts that were more diverse than in original studies.”

PARS was compared to the Asthma Predictive Index (API) in ten cohorts, which included 5,674 children. These cohorts were diverse in terms of race, ethnicity, sex, cohort type, missing data and birth decades. Researchers performed meta-analysis across all ten of the cohorts. PARS and API were applied in each cohort, and researchers compared the ability of both tools to predict asthma’s development between the ages of five and ten.

Researchers found the PARS area under the curve (AUC) was higher than the AUC of the API across nine cohorts out of the ten. The PARS AUC didn’t change based on the cohort type. “Essentially what we saw was that the original PARS scoring was similar to scoring in the new, more diverse cohorts,” said Dr. Biagini. “This validates our previous results and could lead to PARS ultimately becoming a new quantitative gold standard in pediatric asthma risk prediction.”

Visit aaaai.org to learn more about asthma. Research presented at the AAAAI Annual Meeting, February 24-27 in San Antonio, Texas, is published in an online supplement to The Journal of Allergy and Clinical Immunology.

The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organization of more than 7,100 allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. The AAAAI is the go-to resource for patients living with allergies, asthma and immune deficiency disorders. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAI’s Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

Share article on social media or email:

SightMD Welcomes Charles D. Mayron, MD to its Expert Team


News Image

“I was attracted to SightMD’s tradition of commitment to putting the patient care first by having the top equipment, high quality technical team members, and subspecialty excellence with a 7 day a week access for patients.” said Dr Mayron

SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Charles D. Mayron, M.D. to its expert team.

Charles D. Mayron, M.D. is a board-certified ophthalmologist, retinal specialist, and surgeon having over 30 years of experience. Dr. Mayron is experienced in treating macular degeneration/pucker, diabetic retinopathy, flashes and floaters, retinal detachments, and other diseases affecting the posterior section of the human eye. Dr. Mayron completed his vitreo-retinal surgery and medical retina fellowship at the University of Virginia Medical Center and his ophthalmology residency at the New York University Medical Center. He earned his medical degree at New York University. His undergraduate studies were completed at Columbia College, Columbia University. Dr. Mayron’s addition to SightMD expands the retinal eye care capabilities available at the practice. Dr. Mayron will be seeing patients at our locations in Smithtown (260 Middle Country Rd Suite 201, Smithtown, NY 11787) and Bayshore (375 E Main St Suite 24, Bay Shore, NY 11706).

When asked what excites him most about joining the SightMD team, Dr. Mayron said “I was attracted to SightMD’s tradition of commitment to putting the patient care first by having the top equipment, high quality technical team members, and subspecialty excellence with a 7 day a week access for patients. As a New Yorker born, raised and educated and having worked upstate I found it a good opportunity to continue high level care on Long Island which I have spent years visiting family. I hope to continue publishing educational subjects in Retina in the years to come.​​”

SightMD is actively seeking ophthalmology professionals who are interested in joining our outstanding team. If you are an ophthalmology practice owner interested in merging or selling your practice, please contact our VP of Growth, Franc Galinanes, at (631) 396-8340 or fgalinanes@sightgrowthpartners.com

About SightMD

SightMD is a rapidly-growing integrated ophthalmic provider group, offering patients access to over 80 eye care providers through the convenience of 39 locations across New York. SightMD’s track record of providing clinically-excellent care spans over 50 years, and its services include general eye exams, laser cataract surgery and lens implantation, glaucoma management, retinal disorder treatment, corneal services, neuro-ophthalmology, LASIK laser vision correction, oculoplastic surgery, pediatric ophthalmology, and audiology. Sight Growth Partners is the administrative services provider for SightMD. For more information about SightMD, please visit https://www.sightmdny.com

Share article on social media or email:

Metrasens Technology Sees Significant Uptake to Enhance Safety of Hospital Workers from Firearm and Knife Threats


Metrasens Logo

“What impressed us most about the Metrasens Ultra is its incredible flexibility and portability compared with other systems that either require costly facility renovations or require a much larger footprint to operate”, said Matthew Brinkman, System Sr. Director, Security Services for Corewell

Metrasens, a leading provider of advanced detection systems for security and safety applications, today announced its progress in enhancing the safety and security of hospitals and healthcare centers throughout the US. Over the last 6 months, adoption of its technology has accelerated, and more than 180 hospitals and healthcare centers are now working with Metrasens to leverage its technology, training expertise, and customer support.    

Customers range from dedicated behavioral health centers to emergency department psychiatric units, rural independent hospitals, academic hospitals, childrens’ hospitals, and large multi-site urban health systems. Each has its own individual approach to safety, often extending beyond the front door and protection from guns alone.

“Most security leaders and hospital executives we work with acknowledge the risks presented by guns and bladed weapons (knives, box cutters) and, the corresponding need to increase the protection of their staff from these potential threats”, says Brian Solverson, Director of Healthcare Safety for Metrasens. “Knives are a real threat that our customers face and are often a challenge because of how they can be easily concealed and elude detection from other technologies. We are fortunate to have technology that addresses these risks and puts safety first.”

Incidents involving other potential weapons, while less newsworthy than incidents involving guns, are on the rise. In a study of a large urban healthcare system, researchers found that nearly 3% of emergency department visits resulted in the confiscation of weapons (10,691 weapons), with 67% being bladed weapons and 0.3% being guns.

Metrasens customers are achieving impressive results, including this large threat set of bladed weapons. One customer, a level 1 adult and pediatric trauma center with 500 beds, reported preventing over 2,500 risk items in the first five months of their deployment with the Metrasens Ultra system.

Hospitals aim to reverse the trend of violence against staff while maintaining patient care as the primary objective. Metrasens offers a combination of high-performing detection systems that align with the customers’ desired threat sets, and are portable and aesthetically pleasing for added flexibility.    

“What impressed us most about the Metrasens Ultra is its incredible flexibility and portability compared with other systems that either require costly facility renovations or require a much larger footprint to operate”, said Matthew Brinkman, System Senior Director, Security Services for Corewell Health. “Our leadership is happy with our evaluation and decision to add Metrasens Ultra into our security operations.”

Corewell Health, the combination of the former Spectrum Health and Beaumont Health, is the largest employer in the state of Michigan.

“Metrasens has had the pleasure of working with great partners like Corewell Health and many others, and take pride in the fact we are an important part of reducing their workplace violence incidents”, said Simon Goodyear, CEO of Metrasens. “It is humbling and inspiring to know that we can contribute to the safety and security of communities that do so much to ensure our safety as patients in their hospitals.”

About Metrasens

Metrasens is the world’s leading provider of advanced magnetic detection technologies. With a technology center and manufacturing facility in the United Kingdom, a North American sales and customer service hub in Chicago, and a global network of distributors, the company’s innovative products are designed to address deficiencies in conventional screening methods and make the world safer and more secure. Metrasens’ mission is to take cutting-edge science from the laboratory and use it to create revolutionary, award-winning products that meet the distinct and diverse security needs of its customers. Metrasens’ core technologies have a wide range of real-world applications, embodied by solutions that are easy to adopt and simple to use. For more information, visit http://www.metrasens.com.

Share article on social media or email:

Cummings Graduate Institute’s Integrated Care Conference Returns October 9-11, 2023


Register now!

Cummings Graduate Institute for Behavioral Health Studies (CGI) is immensely proud to host the 2023 Integrated Care Conference taking place October 9-11, 2023, at the Gila River Resorts – Wild Horse Pass & Conference Center in Chandler, Arizona. The 2023 CGI Integrated Care Conference theme is Opportunity in Crisis – Using Adverse Pandemic Experiences to Drive Healthcare Improvement. Conference registration will open in May 2023.The 2023 Integrated Care Conference is designed for multidisciplinary healthcare professionals, leaders, researchers, clinicians, community health workers, caregivers, and other stakeholders who are engaged in healthcare design, delivery, and improvement. From vulnerable populations to policy and payment reform – the CGI community drives for better outcomes. We anticipate over 300 attendees from across the US and the globe participating in the conference.

Who should attend:

● Doctors of Behavioral Health (DBHs)

● DBH students and students in healthcare-related fields

● Faculty and subject matter experts

● Integrated care researchers & emerging professionals

● Mental health & social work professionals

● Community health workers

● Nursing professionals

● Physicians and specialists

● Administrative and executive leaders

● Care managers

● Public health professionals

● Health policy advocates

● Patient health & wellness advocates

● Quality improvement professionals

At this time, the conference is accepting presentation and poster proposals. Due to the diversity of integrated care professionals, CGI welcomes presentations with scientific data, clinical innovations, community-designed projects, policy and governance partnerships, and entrepreneurial proposals.​​ The deadline for submissions is April 10, 2023.

To learn more about how to submit a presentation or poster presentation, visit: https://bit.ly/CGIconfprescall Sponsorship opportunities are available. Sponsors of the conference can increase their brand awareness with attendees through sponsorship packages.

To explore sponsorship options for the 2023 Integrated Care Conference, visit: https://bit.ly/CGIconfsponsor

About Cummings Graduate Institute for Behavioral Health Studies (CGI)Cummings Graduate Institute for Behavioral Health Studies is a nonprofit, DEAC accredited, online post-graduate institution of higher learning offering post-graduate education and training in the field of integrated behavioral healthcare. CGI is focused on meeting the healthcare industry’s need for a highly-skilled workforce to support an integrated approach to addressing patients’ needs.

For further information or to arrange interviews, contact:

Cummings Graduate Institute for Behavioral Health Studies

Melissa McGurgan

melissa@cgi.edu

Share article on social media or email:

Memorial Neurosurgery Team First in South Florida to Perform Robotic-Assisted “Asleep” Deep Brain Stimulation to Treat Parkinson’s Disease


Dr. Christopher DeMassi, Chief,
Memorial Neuroscience Institute at
Memorial Healthcare System

“Patients no longer have to be awake and endure an uncomfortable surgery to help subside tremors, and other symptoms of Parkinson’s disease,” said Dr. DeMassi. “By coupling our team’s expertise with the ROSA, we offer a comfortable, safe surgical procedure with only one night stay in the hospital.”

Deep brain stimulation (DBS) is a proven surgical treatment where a neurosurgeon implants electrodes in a specific area of the brain to help relieve tremors and symptoms of stiffness and slowness in patients who have Parkinson’s disease or another movement disorder, such as dystonia. However, traditional DBS surgery can be unpleasant and painful, as it is performed while the patient is awake and requires individuals to stop taking any medications to control their movement disorders.

Memorial Neuroscience Institute is the first in South Florida to offer an advanced method of DBS that is performed while the patient is comfortably asleep under general anesthesia. Using the Robotic Surgical Assistant (ROSA) and an intraoperative computed tomography (CT) scan to precisely target and verify accurate positioning of the DBS electrodes, Dr. Christopher DeMassi, chief of Memorial Neuroscience Institute, and his team successfully completed a robotic-assisted asleep DBS in half the time of a traditional DBS surgery.

“Gone are the days when patients had to be awake and endure an uncomfortable surgery to help subside tremors, stiffness and other symptoms related to Parkinson’s disease,” said Dr. DeMassi. “By coupling our team’s expertise with robotic innovation like the ROSA, we are offering our patients a comfortable, safe surgical procedure that generally requires only one night in the hospital and offers them long-term relief.”

Within a week or two after the initial DBS surgery, the patient returns for a 10-minute outpatient procedure to place a small battery/generator under the skin near the collarbone. The electrodes are then connected to the battery and begin to deliver continuous electrical stimulation to areas of the patient’s brain that carry abnormal signals that produce some symptoms of Parkinson’s disease and other movement disorders.

“Our team of neurologists, neuropsychologists and neurosurgeons perform a detailed evaluation of each patient to determine their care plan,” said Dr. Harsh Gupta, neurologist who specializes in movement disorders at Memorial Neuroscience Institute. “Generally, the DBS procedure benefits patients who no longer respond to medications that reduce symptoms of movement disorders or are having significant side effects from these medications.”

Patients who want to learn more about DBS should speak with their neurologist or primary care physician who may refer them to Memorial Neuroscience Institute. To learn more about Memorial Neuroscience Institute, visit http://www.mhs.net/neuroscience or call 954-265-9500.

About Memorial Neuroscience Institute

Memorial Neuroscience Institute offers expertise in stroke, brain aneurysms, brain arteriovenous malformations, brain tumors, epilepsy, MS, neuromuscular disorders, spine disorders, movement disorders and more. Featuring a multidisciplinary team of experts, Memorial provides advanced diagnoses, leading-edge treatments, compassionate care, rehabilitation, and complete follow-up for some of the most complex neurological conditions and injuries. Neurosurgeons, neurologists, neurointerventional surgeons, neuro-oncologists, neurocritical care physicians and neuropsychologists, among others, collaborate to provide a complete continuum of neurological care. For additional information, http://www.mhs.net/neuroscience.

###

Share article on social media or email: